AIM2-driven inflammasome activation in heart failure.

Cardiovascular Research
Zsófia OnódiZoltán V Varga

Abstract

Interleukin-1β (IL-1β) is an important pathogenic factor in cardiovascular diseases including chronic heart failure (HF). The CANTOS trial highlighted that inflammasomes as primary sources of IL-1 β are promising new therapeutic targets in cardiovascular diseases. Therefore, we aimed to assess inflammasome activation in failing hearts to identify activation patterns of inflammasome subtypes as sources of IL-1β. Out of the four major inflammasome sensors tested, expression of the inflammasome protein absent in melanoma 2 (AIM2) and NLR family CARD domain-containing protein 4 (NLRC4) increased in human HF regardless of the aetiology (ischaemic or dilated cardiomyopathy), while the NLRP1/NALP1 and NLRP3 (NLR family, pyrin domain containing 1 and 3) inflammasome showed no change in HF samples. AIM2 expression was primarily detected in monocytes/macrophages of failing hearts. Translational animal models of HF (pressure or volume overload, and permanent coronary artery ligation in rat, as well as ischaemia/reperfusion-induced HF in pigs) demonstrated activation pattern of AIM2 similar to that of observed in end-stages of human HF. In vitro AIM2 inflammasome activation in human Tohoku Hospital Pediatrics-1 (THP-1) monocytic cells and ...Continue Reading

References

Nov 7, 2002·International Journal of Cardiology·Stefan D Anker, Andrew J S Coats
Jan 18, 2003·Journal of Applied Physiology·Xi WangNaranjan S Dhalla
Jun 11, 2004·Nature·Sanjeev MariathasanVishva M Dixit
Dec 14, 2006·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J Alain KummerJürg Tschopp
Dec 11, 2008·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Denise P AbulafiaW Dalton Dietrich
May 7, 2009·The Journal of Biological Chemistry·William R SilvermanGerhard Dahl
Nov 23, 2011·Proceedings of the National Academy of Sciences of the United States of America·Eleonora MezzaromaAntonio Abbate
Dec 18, 2012·Journal of Cardiovascular Pharmacology and Therapeutics·Sheryl E KochJack Rubinstein
Mar 17, 2015·Proceedings of the National Academy of Sciences of the United States of America·Adam DenesDavid Brough
May 22, 2016·Journal of the American Heart Association·Geena Paramel VargheseAllan Sirsjö
Jun 25, 2016·Circulation Research·Sumanth D Prabhu, Nikolaos G Frangogiannis
Sep 17, 2016·Circulation Research·Bijun Chen, Nikolaos G Frangogiannis
Oct 16, 2016·Biochimica Et Biophysica Acta. Molecular Cell Research·Sara Crespo YanguasMathieu Vinken
May 27, 2017·European Heart Journal·Han XiaoYou-Yi Zhang
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Dec 6, 2017·Frontiers in Physiology·Zoltán V VargaPéter Ferdinandy
Feb 14, 2018·Journal of the American Society of Nephrology : JASN·Takanori KomadaDaniel A Muruve
Mar 3, 2018·Journal of the American College of Cardiology·Seoyoung C KimDaniel H Solomon
Aug 1, 2018·JACC. Basic to Translational Science·Bijun Chen, Nikolaos G Frangogiannis
Oct 9, 2018·European Heart Journal·Thomas F Lüscher
Nov 10, 2018·Nature Reviews. Cardiology·W H Wilson TangStanley L Hazen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

© 2021 Meta ULC. All rights reserved